(Q35569491)

English

Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

scientific article published on 22 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

0 references

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tait D Shanafelt

6

object named as

Tait D Shanafelt

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Timothy G. Call

9

object named as

Timothy G Call

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1

object named as

Clive S Zent

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

7

object named as

Neil E Kay

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Wenting Wu

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Deborah A Bowen

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Curtis A Hanson

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Adam M Pettinger

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Jose F Leis

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

476-482

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Understanding and managing ultra high-risk chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Blood monocytes: development, heterogeneity, and relationship with dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Effect of alemtuzumab on neoplastic B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

12 July 2018

Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717276

21 January 2018

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717276

21 January 2018

Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717276

21 January 2018

Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717276

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717276

21 January 2018

Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717276

21 January 2018

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419690

26 September 2018

Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22853816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining the prognosis of early stage chronic lymphocytic leukaemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22853816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/22853816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22853816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22853816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

1 reference

https://pubmed.ncbi.nlm.nih.gov/22853816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22853816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/10428194.2012.717276

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35569491&oldid=1861440552"